NCT04480723View on ClinicalTrials.gov

A Study for the Identification of Biomarker Signatures for Diagnosis of Pulmonary Hypertension (PH) in Participants at Low or Intermediate Probability of PH Undergoing Cardiac Magnetic Resonance Imaging

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

December 11, 2020

Primary Completion Date

May 13, 2022

Study Completion Date

May 18, 2022

Conditions
Hypertension, Pulmonary
Interventions
OTHER

Blood Sample

Blood samples will be taken and analyzed to evaluate the presence of PH.

DIAGNOSTIC_TEST

Cardiac MRI

Cardiac MRI will be performed to evaluate the presence of PH.

Trial Locations (8)

23538

Universitatsklinikum Schleswig Holstein, Lübeck

35392

Universitaetsklinikum Giessen, Giessen

53105

Universitatsklinikum Bonn, Bonn

BA1 3NG

Royal United Hospital, Bath

G81 4DY

National Waiting Times Centre Board Golden Jubilee National Hospital, Glasgow

NW3 2QG

Royal Free Hospital, London

W12 0HS

Hammersmith Hospital, London

S10 2RX

Sheffield Teaching Hospitals NHS Foundation Trust Royal Hallamshire Hospital, Sheffield

Sponsors

Lead Sponsor

Actelion
All Listed Sponsors
lead

Actelion

INDUSTRY

NCT04480723 - A Study for the Identification of Biomarker Signatures for Diagnosis of Pulmonary Hypertension (PH) in Participants at Low or Intermediate Probability of PH Undergoing Cardiac Magnetic Resonance Imaging | Biotech Hunter | Biotech Hunter